Hubertus G Leufkens (Hubert G M Leufkens)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Topics

Sickle Cell Disease

Transcription Factor

Neuropathic Pain

Top Venues

Clinical pharmacology and therapeutics

Journal of medical Internet research

Cadernos de saude publica

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics 116 (1) (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Doerine J Postma, Magali L A Heijkoop, P A G M Peter De Smet, Kim Notenboom, Hubertus G Leufkens, Aukje K Mantel-Teeuwisse
Identifying Medicine Shortages With the Twitter Social Network: Retrospective Observational Study. Journal of medical Internet research 26 (2024)
Doerine J Postma, Magali L A Heijkoop, P A G M Peter De Smet, Kim Notenboom, Hubertus G Leufkens, Aukje K Mantel-Teeuwisse
Identifying Medicine Shortages With the Twitter Social Network: Retrospective Observational Study. Journal of medical Internet research 26 (2024)
Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics 116 (1) (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
SUCCESSES AND PITFALLS IN ORPHAN DRUG DEVELOPMENT FOR SICKLE CELL DISEASE. Blood advances (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Anna Maria Gerdina Pasmooij, Peter G M Mol, Jacob Cornelis Bot, Hubertus G Leufkens
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clinical pharmacology and therapeutics (2024)
Rick A Vreman, Huseyin Naci, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Sebastian G Schneeweiss, Hubertus G Leufkens, Aaron S Kesselheim
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical pharmacology and therapeutics 108 (2) (2020)
Rogério Hoefler, Teresa Leonardo Alves, Hubertus G Leufkens, Janeth de Oliveira Silva Naves
Added therapeutic value of new drugs approved in Brazil from 2004 to 2016. Cadernos de saude publica 35 (5) (2019)